KSB 306/7

Drug Profile

KSB 306/7

Alternative Names: KSB 306; KSB 307

Latest Information Update: 01 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KS Biomedix Holdings
  • Developer KS Biomedix Holdings; Sosei R&D
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 01 Oct 2002 Discontinued - Preclinical for Osteoarthritis in United Kingdom (unspecified route)
  • 01 Oct 2002 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
  • 25 May 2001 Preclinical development for Osteoarthritis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top